Long-Term Efficacy and Safety of Evocalcet in Japanese Patients with Secondary Hyperparathyroidism Receiving Hemodialysis
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
2045-2322
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
Long-Term Efficacy and Safety of Evocalcet in Japanese Patients with Secondary Hyperparathyroidism Receiving Hemodialysis ; volume:9 ; number:1 ; day:23 ; month:4 ; year:2019 ; pages:1-11 ; date:12.2019
Scientific reports ; 9, Heft 1 (23.4.2019), 1-11, 12.2019
- Classification
-
Naturwissenschaften
- Creator
-
Yokoyama, Keitaro
Shimazaki, Ryutaro
Fukagawa, Masafumi
Akizawa, Tadao
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1038/s41598-019-42017-z
- URN
-
urn:nbn:de:101:1-2019051119292858738409
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
14.08.2025, 11:02 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Yokoyama, Keitaro
- Shimazaki, Ryutaro
- Fukagawa, Masafumi
- Akizawa, Tadao
- SpringerLink (Online service)
Other Objects (12)
Pharmacodynamics of evocalcet for secondary hyperparathyroidism in Japanese hemodialysis patients
Hemodialysis patients’ preferences for the management of secondary hyperparathyroidism
Cinacalcet studies in pediatric subjects with secondary hyperparathyroidism receiving dialysis
Parathyroidectomy Versus Cinacalcet for the Treatment of Secondary Hyperparathyroidism in Hemodialysis Patients
Long-Term Efficacy and Safety of Upacicalcet in Japanese Hemodialysis Patients with Secondary Hyperparathyroidism: Open-Label 52-Week Study
Treatment with cinacalcet increases plasma sclerostin concentration in hemodialysis patients with secondary hyperparathyroidism
Long-term treatment of evocalcet in hemodialysis patients with secondary hyperparathyroidism: a five-year prospective cohort study in 147 Japanese patients
First-in-Patient Phase I/II Study of Upacicalcet in Japanese Patients with Secondary Hyperparathyroidism Undergoing Hemodialysis: Pharmacokinetic and Pharmacodynamic Properties
Relationship between parathyroid mass and parathyroid hormone level in hemodialysis patients with secondary hyperparathyroidism
Observation of the efficacy of parathyroidectomy for secondary hyperparathyroidism in hemodialysis patients: a retrospective study
Recurrent tertiary hyperparathyroidism due to supernumerary parathyroid glands in a patient receiving long-term hemodialysis: a case report
Partial response to cinacalcet treatment in a patient with secondary hyperparathyroidism undergoing hemodialysis: a case report
Pharmacodynamics of evocalcet for secondary hyperparathyroidism in Japanese hemodialysis patients
Hemodialysis patients’ preferences for the management of secondary hyperparathyroidism
Cinacalcet studies in pediatric subjects with secondary hyperparathyroidism receiving dialysis
Parathyroidectomy Versus Cinacalcet for the Treatment of Secondary Hyperparathyroidism in Hemodialysis Patients
Long-Term Efficacy and Safety of Upacicalcet in Japanese Hemodialysis Patients with Secondary Hyperparathyroidism: Open-Label 52-Week Study
Treatment with cinacalcet increases plasma sclerostin concentration in hemodialysis patients with secondary hyperparathyroidism
Long-term treatment of evocalcet in hemodialysis patients with secondary hyperparathyroidism: a five-year prospective cohort study in 147 Japanese patients
First-in-Patient Phase I/II Study of Upacicalcet in Japanese Patients with Secondary Hyperparathyroidism Undergoing Hemodialysis: Pharmacokinetic and Pharmacodynamic Properties
Relationship between parathyroid mass and parathyroid hormone level in hemodialysis patients with secondary hyperparathyroidism
Observation of the efficacy of parathyroidectomy for secondary hyperparathyroidism in hemodialysis patients: a retrospective study
Recurrent tertiary hyperparathyroidism due to supernumerary parathyroid glands in a patient receiving long-term hemodialysis: a case report
Partial response to cinacalcet treatment in a patient with secondary hyperparathyroidism undergoing hemodialysis: a case report
Pharmacodynamics of evocalcet for secondary hyperparathyroidism in Japanese hemodialysis patients
Hemodialysis patients’ preferences for the management of secondary hyperparathyroidism
Cinacalcet studies in pediatric subjects with secondary hyperparathyroidism receiving dialysis
Parathyroidectomy Versus Cinacalcet for the Treatment of Secondary Hyperparathyroidism in Hemodialysis Patients
Long-Term Efficacy and Safety of Upacicalcet in Japanese Hemodialysis Patients with Secondary Hyperparathyroidism: Open-Label 52-Week Study
Treatment with cinacalcet increases plasma sclerostin concentration in hemodialysis patients with secondary hyperparathyroidism
Long-term treatment of evocalcet in hemodialysis patients with secondary hyperparathyroidism: a five-year prospective cohort study in 147 Japanese patients
First-in-Patient Phase I/II Study of Upacicalcet in Japanese Patients with Secondary Hyperparathyroidism Undergoing Hemodialysis: Pharmacokinetic and Pharmacodynamic Properties
Relationship between parathyroid mass and parathyroid hormone level in hemodialysis patients with secondary hyperparathyroidism
Observation of the efficacy of parathyroidectomy for secondary hyperparathyroidism in hemodialysis patients: a retrospective study
Recurrent tertiary hyperparathyroidism due to supernumerary parathyroid glands in a patient receiving long-term hemodialysis: a case report